Cargando…
Human Epidermal Growth Factor Receptor 2 Overexpression and Amplification in Patients With Colorectal Cancer: A Large-Scale Retrospective Study in Chinese Population
BACKGROUND: Cumulative evidence in colorectal cancer (CRC) suggests that patients with human epidermal growth factor receptor 2 (HER2) overexpression or amplification can benefit from anti-HER2 therapy. The purpose of our study was to evaluate HER2 status and its correlation with clinicopathological...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097912/ https://www.ncbi.nlm.nih.gov/pubmed/35574415 http://dx.doi.org/10.3389/fonc.2022.842787 |
_version_ | 1784706267525152768 |
---|---|
author | Ni, Shujuan Wang, Xin Chang, Jinjia Sun, Hui Weng, Weiwei Wang, Xu Tan, Cong Zhang, Meng Wang, Lei Huang, Zhaohui Huang, Dan Xu, Midie Sheng, Weiqi |
author_facet | Ni, Shujuan Wang, Xin Chang, Jinjia Sun, Hui Weng, Weiwei Wang, Xu Tan, Cong Zhang, Meng Wang, Lei Huang, Zhaohui Huang, Dan Xu, Midie Sheng, Weiqi |
author_sort | Ni, Shujuan |
collection | PubMed |
description | BACKGROUND: Cumulative evidence in colorectal cancer (CRC) suggests that patients with human epidermal growth factor receptor 2 (HER2) overexpression or amplification can benefit from anti-HER2 therapy. The purpose of our study was to evaluate HER2 status and its correlation with clinicopathological characteristics and survival according to currently utilized HER2 diagnostic criteria in a large cohort of Chinese CRC patients. METHODS: HER2 protein expression was tested by immunohistochemistry (IHC) in formalin-fixed, paraffin-embedded (FFPE) samples from 4,836 CRC patients in our institution. Breast cancer (BC) and gastroesophageal adenocarcinoma (GEA) criteria, as well as the HERACLES criteria, were used for the determination of HER2 status. Dual-color silver-enhanced in situ hybridization (DSISH) was performed in all IHC 2+~3+ cases determined by BC/GEA criteria. RESULTS: The HER2 expression rate of IHC (1+~3+) was 7.01% (339/4,836) and 6.02% (291/4,836) in CRCs based on the BC/GEA criteria and the HERACLES criteria, respectively, while combined DSISH results in the HER2 amplification/overexpression ratio of 3.39% (164/4,836) in our cohort. HER2 expression detected by IHC was positively correlated with the female gender, whereas the HER2 overexpression/amplification showed no correlation with any clinicopathological parameter. In addition, no significant correlation was found between HER2 statuses and either disease-free survival or overall survival regardless of the evaluation criterion used. However, patients with HER2 1+ CRC showed a tendency of having the shortest overall survival as compared with any other group of patients according to the HERACLES criteria, and this trend has always existed in the rectal location, T3 stage, and TNM stage II, medium differentiation, and perineural invasion stratified group. Furthermore, the HER2 protein expression was significantly negatively correlated with RAS/BRAF mutations according to the HERACLES criteria. CONCLUSION: To our knowledge, this is the largest study of HER2 status in Asian patients with CRC. Our findings suggest that the current most commonly used HERACLES criteria might be too strict for patients with CRC. Future studies are needed to explore the most suitable criteria for screening CRC patients who could benefit from anti-HER2 therapy as much as possible. |
format | Online Article Text |
id | pubmed-9097912 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90979122022-05-13 Human Epidermal Growth Factor Receptor 2 Overexpression and Amplification in Patients With Colorectal Cancer: A Large-Scale Retrospective Study in Chinese Population Ni, Shujuan Wang, Xin Chang, Jinjia Sun, Hui Weng, Weiwei Wang, Xu Tan, Cong Zhang, Meng Wang, Lei Huang, Zhaohui Huang, Dan Xu, Midie Sheng, Weiqi Front Oncol Oncology BACKGROUND: Cumulative evidence in colorectal cancer (CRC) suggests that patients with human epidermal growth factor receptor 2 (HER2) overexpression or amplification can benefit from anti-HER2 therapy. The purpose of our study was to evaluate HER2 status and its correlation with clinicopathological characteristics and survival according to currently utilized HER2 diagnostic criteria in a large cohort of Chinese CRC patients. METHODS: HER2 protein expression was tested by immunohistochemistry (IHC) in formalin-fixed, paraffin-embedded (FFPE) samples from 4,836 CRC patients in our institution. Breast cancer (BC) and gastroesophageal adenocarcinoma (GEA) criteria, as well as the HERACLES criteria, were used for the determination of HER2 status. Dual-color silver-enhanced in situ hybridization (DSISH) was performed in all IHC 2+~3+ cases determined by BC/GEA criteria. RESULTS: The HER2 expression rate of IHC (1+~3+) was 7.01% (339/4,836) and 6.02% (291/4,836) in CRCs based on the BC/GEA criteria and the HERACLES criteria, respectively, while combined DSISH results in the HER2 amplification/overexpression ratio of 3.39% (164/4,836) in our cohort. HER2 expression detected by IHC was positively correlated with the female gender, whereas the HER2 overexpression/amplification showed no correlation with any clinicopathological parameter. In addition, no significant correlation was found between HER2 statuses and either disease-free survival or overall survival regardless of the evaluation criterion used. However, patients with HER2 1+ CRC showed a tendency of having the shortest overall survival as compared with any other group of patients according to the HERACLES criteria, and this trend has always existed in the rectal location, T3 stage, and TNM stage II, medium differentiation, and perineural invasion stratified group. Furthermore, the HER2 protein expression was significantly negatively correlated with RAS/BRAF mutations according to the HERACLES criteria. CONCLUSION: To our knowledge, this is the largest study of HER2 status in Asian patients with CRC. Our findings suggest that the current most commonly used HERACLES criteria might be too strict for patients with CRC. Future studies are needed to explore the most suitable criteria for screening CRC patients who could benefit from anti-HER2 therapy as much as possible. Frontiers Media S.A. 2022-04-28 /pmc/articles/PMC9097912/ /pubmed/35574415 http://dx.doi.org/10.3389/fonc.2022.842787 Text en Copyright © 2022 Ni, Wang, Chang, Sun, Weng, Wang, Tan, Zhang, Wang, Huang, Huang, Xu and Sheng https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Ni, Shujuan Wang, Xin Chang, Jinjia Sun, Hui Weng, Weiwei Wang, Xu Tan, Cong Zhang, Meng Wang, Lei Huang, Zhaohui Huang, Dan Xu, Midie Sheng, Weiqi Human Epidermal Growth Factor Receptor 2 Overexpression and Amplification in Patients With Colorectal Cancer: A Large-Scale Retrospective Study in Chinese Population |
title | Human Epidermal Growth Factor Receptor 2 Overexpression and Amplification in Patients With Colorectal Cancer: A Large-Scale Retrospective Study in Chinese Population |
title_full | Human Epidermal Growth Factor Receptor 2 Overexpression and Amplification in Patients With Colorectal Cancer: A Large-Scale Retrospective Study in Chinese Population |
title_fullStr | Human Epidermal Growth Factor Receptor 2 Overexpression and Amplification in Patients With Colorectal Cancer: A Large-Scale Retrospective Study in Chinese Population |
title_full_unstemmed | Human Epidermal Growth Factor Receptor 2 Overexpression and Amplification in Patients With Colorectal Cancer: A Large-Scale Retrospective Study in Chinese Population |
title_short | Human Epidermal Growth Factor Receptor 2 Overexpression and Amplification in Patients With Colorectal Cancer: A Large-Scale Retrospective Study in Chinese Population |
title_sort | human epidermal growth factor receptor 2 overexpression and amplification in patients with colorectal cancer: a large-scale retrospective study in chinese population |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097912/ https://www.ncbi.nlm.nih.gov/pubmed/35574415 http://dx.doi.org/10.3389/fonc.2022.842787 |
work_keys_str_mv | AT nishujuan humanepidermalgrowthfactorreceptor2overexpressionandamplificationinpatientswithcolorectalcanceralargescaleretrospectivestudyinchinesepopulation AT wangxin humanepidermalgrowthfactorreceptor2overexpressionandamplificationinpatientswithcolorectalcanceralargescaleretrospectivestudyinchinesepopulation AT changjinjia humanepidermalgrowthfactorreceptor2overexpressionandamplificationinpatientswithcolorectalcanceralargescaleretrospectivestudyinchinesepopulation AT sunhui humanepidermalgrowthfactorreceptor2overexpressionandamplificationinpatientswithcolorectalcanceralargescaleretrospectivestudyinchinesepopulation AT wengweiwei humanepidermalgrowthfactorreceptor2overexpressionandamplificationinpatientswithcolorectalcanceralargescaleretrospectivestudyinchinesepopulation AT wangxu humanepidermalgrowthfactorreceptor2overexpressionandamplificationinpatientswithcolorectalcanceralargescaleretrospectivestudyinchinesepopulation AT tancong humanepidermalgrowthfactorreceptor2overexpressionandamplificationinpatientswithcolorectalcanceralargescaleretrospectivestudyinchinesepopulation AT zhangmeng humanepidermalgrowthfactorreceptor2overexpressionandamplificationinpatientswithcolorectalcanceralargescaleretrospectivestudyinchinesepopulation AT wanglei humanepidermalgrowthfactorreceptor2overexpressionandamplificationinpatientswithcolorectalcanceralargescaleretrospectivestudyinchinesepopulation AT huangzhaohui humanepidermalgrowthfactorreceptor2overexpressionandamplificationinpatientswithcolorectalcanceralargescaleretrospectivestudyinchinesepopulation AT huangdan humanepidermalgrowthfactorreceptor2overexpressionandamplificationinpatientswithcolorectalcanceralargescaleretrospectivestudyinchinesepopulation AT xumidie humanepidermalgrowthfactorreceptor2overexpressionandamplificationinpatientswithcolorectalcanceralargescaleretrospectivestudyinchinesepopulation AT shengweiqi humanepidermalgrowthfactorreceptor2overexpressionandamplificationinpatientswithcolorectalcanceralargescaleretrospectivestudyinchinesepopulation |